IBDEI1NI ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26366,0)
 ;;=E10.44^^107^1240^1
 ;;^UTILITY(U,$J,358.3,26366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26366,1,3,0)
 ;;=3^DM Type 1 w/ Diab Amyotrophy
 ;;^UTILITY(U,$J,358.3,26366,1,4,0)
 ;;=4^E10.44
 ;;^UTILITY(U,$J,358.3,26366,2)
 ;;=^5002608
 ;;^UTILITY(U,$J,358.3,26367,0)
 ;;=E10.49^^107^1240^25
 ;;^UTILITY(U,$J,358.3,26367,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26367,1,3,0)
 ;;=3^DM Type 1 w/ Oth Diab Neurological Compl
 ;;^UTILITY(U,$J,358.3,26367,1,4,0)
 ;;=4^E10.49
 ;;^UTILITY(U,$J,358.3,26367,2)
 ;;=^5002609
 ;;^UTILITY(U,$J,358.3,26368,0)
 ;;=E10.59^^107^1240^22
 ;;^UTILITY(U,$J,358.3,26368,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26368,1,3,0)
 ;;=3^DM Type 1 w/ Oth Circulatory Compl
 ;;^UTILITY(U,$J,358.3,26368,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,26368,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,26369,0)
 ;;=E10.610^^107^1240^9
 ;;^UTILITY(U,$J,358.3,26369,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26369,1,3,0)
 ;;=3^DM Type 1 w/ Diab Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,26369,1,4,0)
 ;;=4^E10.610
 ;;^UTILITY(U,$J,358.3,26369,2)
 ;;=^5002613
 ;;^UTILITY(U,$J,358.3,26370,0)
 ;;=E10.618^^107^1240^23
 ;;^UTILITY(U,$J,358.3,26370,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26370,1,3,0)
 ;;=3^DM Type 1 w/ Oth Diab Arthropathy
 ;;^UTILITY(U,$J,358.3,26370,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,26370,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,26371,0)
 ;;=E10.630^^107^1240^30
 ;;^UTILITY(U,$J,358.3,26371,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26371,1,3,0)
 ;;=3^DM Type 1 w/ Peridontal Disease
 ;;^UTILITY(U,$J,358.3,26371,1,4,0)
 ;;=4^E10.630
 ;;^UTILITY(U,$J,358.3,26371,2)
 ;;=^5002619
 ;;^UTILITY(U,$J,358.3,26372,0)
 ;;=E10.638^^107^1240^27
 ;;^UTILITY(U,$J,358.3,26372,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26372,1,3,0)
 ;;=3^DM Type 1 w/ Oth Oral Compl
 ;;^UTILITY(U,$J,358.3,26372,1,4,0)
 ;;=4^E10.638
 ;;^UTILITY(U,$J,358.3,26372,2)
 ;;=^5002620
 ;;^UTILITY(U,$J,358.3,26373,0)
 ;;=E10.641^^107^1240^15
 ;;^UTILITY(U,$J,358.3,26373,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26373,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,26373,1,4,0)
 ;;=4^E10.641
 ;;^UTILITY(U,$J,358.3,26373,2)
 ;;=^5002621
 ;;^UTILITY(U,$J,358.3,26374,0)
 ;;=E10.649^^107^1240^16
 ;;^UTILITY(U,$J,358.3,26374,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26374,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,26374,1,4,0)
 ;;=4^E10.649
 ;;^UTILITY(U,$J,358.3,26374,2)
 ;;=^5002622
 ;;^UTILITY(U,$J,358.3,26375,0)
 ;;=E10.65^^107^1240^14
 ;;^UTILITY(U,$J,358.3,26375,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26375,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,26375,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,26375,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,26376,0)
 ;;=E10.69^^107^1240^29
 ;;^UTILITY(U,$J,358.3,26376,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26376,1,3,0)
 ;;=3^DM Type 1 w/ Oth Spec Compl
 ;;^UTILITY(U,$J,358.3,26376,1,4,0)
 ;;=4^E10.69
 ;;^UTILITY(U,$J,358.3,26376,2)
 ;;=^5002624
 ;;^UTILITY(U,$J,358.3,26377,0)
 ;;=E10.8^^107^1240^33
 ;;^UTILITY(U,$J,358.3,26377,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26377,1,3,0)
 ;;=3^DM Type 1 w/ Unspec Compl
 ;;^UTILITY(U,$J,358.3,26377,1,4,0)
 ;;=4^E10.8
 ;;^UTILITY(U,$J,358.3,26377,2)
 ;;=^5002625
 ;;^UTILITY(U,$J,358.3,26378,0)
 ;;=E10.9^^107^1240^34
